9/5/2023 0 Comments Keynote 59012% of patients discontinuing treatment due to such events. Grade 3 to grade 5 drug-related adverse events occurred among 72% of patients who received pembrolizumab and 68% of those who received placebo, with 19% vs. 0001), with a median duration of response of 8.3 months vs. Researchers reported confirmed ORRs among all patients of 45% with pembrolizumab vs. The pembrolizumab regimen also demonstrated superior median PFS among patients with ESCC (6.3 months vs. Results showed the pembrolizumab regimen demonstrated superior median OS compared with the placebo regimen among patients with ESCC and a PD-L1 CPS of 10 or greater (13.9 months vs. ![]() OS among patients with ESCC and a PD-L1 combined positive score (CPS) of 10 or greater, as well as OS and PFS among patients with ESCC, a PD-L1 CPS of 10 or greater and all patients, served as primary endpoints of this study. ![]() Patients continued treatment for 2 years or until progression, unacceptable toxicity or study withdrawal. ESCC, and ECOG performance status of 0 vs. the rest of the world, adenocarcinoma vs. They stratified randomization by Asia vs. chemotherapy alone among 749 patients (83% men) with locally advanced/unresectable or metastatic adenocarcinoma or esophageal squamous cell carcinoma (ESCC, 73%) or Siewert type I esophagogastric junction adenocarcinoma.Įnzinger and colleagues randomly assigned patients to either pembrolizumab dosed at 200 mg every 3 weeks for up to 2 years (n = 373) or placebo (n = 376) with 80 mg/m 2 cisplatin every 3 weeks plus 800 mg/m 2 5-FU on days 1 to 5 every 3 weeks. The international, double-blind KEYNOTE-590 trial analyzed pembrolizumab plus chemotherapy vs. Two previous KEYNOTE studies showed monotherapy with the anti-PD-1 agent pembrolizumab (Keytruda, Merck) induced antitumor activity in advanced or metastatic esophageal cancer. “Fluoropyrimidine plus platinum-based chemotherapy has been the standard in the first line, docetaxel, paclitaxel, irinotecan and ramucirumab with or without paclitaxel is standard in the second line or for adenocarcinoma.” Enzinger, MD, director of the Center for Esophageal and Gastric Cancer at Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School, said during a press conference. ![]() “Unfortunately, for esophageal cancer, the standard of care has remained relatively unchanged for a long period of time,” Peter C. The combination also had an acceptable safety profile and represents a new standard of care for this patient population, according to the findings, presented at ESMO Virtual Congress 2020. The addition of pembrolizumab to chemotherapy improved OS, PFS and objective response rates among patients with untreated, advanced esophageal and esophagogastric junction adenocarcinoma, results of the phase 3 KEYNOTE-590 study showed. If you continue to have this issue please contact to Healio
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |